Vaxart Q1 Net Loss Widens as Revenue Declines
4:55AM ET 5/10/2022 MT NewswiresVaxart (VXRT) reported a Q1 net loss Monday of $0.20 per diluted share, widening from a $0.14 loss a year earlier. Four analysts polled by Capital IQ...
Quotes Snapshot > VXRT
Vaxart Inc VXRT:NASDAQ
Last Price$3.16NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22
Today's Change-0.22(6.51%)
Bid (Size)$3.03 (1)
Ask (Size)$3.50 (2)
Day Low / High$3.04 - 3.33
Volume2.8 M
Read more news Recent News
--B. Riley Lowers Vaxart's Price Target to $7 from $9 to Reflect Long Term Higher Cost of Capital Amid Current Macro Conditions, Keeps Neutral Rating
8:36AM ET 3/07/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform
3:24AM ET 2/26/2022 Seeking AlphaVaxart (VXRT) Investor Presentation - Slideshow
6:57PM ET 1/21/2022 Seeking AlphaValue And Momentum MDA Breakouts +70.5% In 52 Weeks: Final 2021 Year End Report Card
7:05PM ET 12/30/2021 Seeking AlphaVaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow
2:41PM ET 12/09/2021 Seeking AlphaCompany Profile
Business DescriptionVaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 170 Harbor Way South San Francisco, California 94080 |
| Phone | +1.650.550.3500 |
| Number of Employees | 34 |
| Recent SEC Filing | 05/18/2022 DEFA14A |
| President, Chief Executive Officer & Director | Andrei Floroiu |
| Chief Financial Officer | Fuad Ahmad |
| Chief Scientific Officer & Senior Vice President | Sean N. Tucker |
| Senior Vice President-Technical Operations | Richard Schwartz |
Company Highlights
| Price Open | $3.27 |
| Previous Close | $3.16 |
| 52 Week Range | $2.49 - 10.33 |
| Market Capitalization | $399.4 M |
| Shares Outstanding | 126.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.56 |
| Beta vs. S&P 500 | N/A |
| Revenue | $4.2 M |
| Net Profit Margin | -7,900.22% |
| Return on Equity | -36.68% |
Analyst Ratings as of 05/10/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |